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Pro-inﬂammatory cytokines like interleukin-1 beta (IL-1) are major players in the interaction between
the immune system and the central nervous system. Various animal studies report a sleep-promoting
effect of IL-1 leading to enhanced slow wave sleep (SWS). Moreover, this cytokine was shown to affect
hippocampus-dependent memory. However, the role of IL-1 in human sleep and memory is not yet
understood. We administered the synthetic IL-1 receptor antagonist anakinra (IL-1ra) in healthy humans
(100 mg, subcutaneously, before sleep; n = 16) to investigate the role of IL-1 signaling in sleep regulation
and sleep-dependent declarative memory consolidation. Inasmuch monocytes have been considered a
model for central nervous microglia, we monitored cytokine production in classical and non-classical
blood monocytes to gain clues about how central nervous effects of IL-1ra are conveyed. Contrary to
our expectation, IL-1ra increased EEG slow wave activity during SWS and non-rapid eye movement (Non-
REM) sleep, indicating a deepening of sleep, while sleep-associated memory consolidation remained
unchanged. Moreover, IL-1ra slightly increased prolactin and reduced cortisol levels during sleep. Produc-
tion of IL-1 by classical monocytes was diminished after IL-1ra. The discrepancy to ﬁndings in animal
studies might reﬂect species differences and underlines the importance of studying cytokine effects in
humans.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Sleep and the immune system are thought to interact such that
sleep promotes immune defense and immune responses to infec-
tious agents convey an enhancing inﬂuence on sleep (Besedovsky
et al., 2012; Imeri and Opp, 2009). Stimulated by early work that
identiﬁed a muramyl peptide, i.e., a fragment of bacterial cell walls,
as potent sleep promoting factor (Krueger et al., 1982), the idea has
been around for a long time that pro-inﬂammatory cytokines that
are released in response to microbial challenge are involved in the
homeostatic regulation of sleep, especially of slow wave sleep
(SWS) (Krueger and Majde, 1994; Krueger et al., 1995). Interleu-
kin-1 beta (IL-1) and tumor necrosis factor (TNF), two important
cytokines mediating inﬂammatory processes, are considered majorplayers in this context (Krueger et al., 2007). Intracerebroventricu-
lar (i.c.v.) injection of IL-1 and TNF enhances non-rapid eye move-
ment (NonREM) sleep duration and slowwave activity in rats, mice
and rabbits, whereas inhibition of IL-1 signaling diminishes Non-
REM sleep in these species (Krueger et al., 2007; Obál and
Krueger, 2003). Whereas initially these cytokines were assumed
to originate from peripheral sites, more recent research focused
on brain microglia and macrophages as crucial source of IL-1 and
TNF, both of which are released during synaptic activity and pro-
mote SWS also under normal physiological conditions, i.e., in the
absence of any infectious challenge (Krueger et al., 2008). Apart
from regulating sleep, microglial pro-inﬂammatory cytokines are
involved in plastic neuronal processes underlying memory forma-
tion in the hippocampus (Williamson et al., 2011). Both IL-1 and
TNF contribute to synaptic long-term potentiation (LTP), a major
mechanism underlying the formation of neuronal memory repre-
sentations (Ben Menachem-Zidon et al., 2011; del Rey et al.,
2013; Gruber-Schoffnegger et al., 2013; Schneider et al., 1998).
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robust enhancements of NonREM sleep with opposite effects after
blocking respective receptors (e.g., Opp and Krueger, 1991;
Takahashi et al., 1996b, 1997), there is an obvious paucity of stud-
ies of such cytokines in humans. Minocycline which directly sup-
presses microglial activation in an anti-inﬂammatory manner,
decreased SWS and NonREM sleep in humans and animals, respec-
tively (Nonaka et al., 1983; Wisor et al., 2011). In pilot studies,
patients with rheumatoid arthritis and obstructive sleep apnea
showed a decrease in sleepiness after blocking of IL-1 and TNF-sig-
naling, respectively (Omdal and Gunnarsson, 2005; Vgontzas et al.,
2004). In another study, abstinent patients with alcohol depen-
dence showed a robust decrease in REM sleep following treatment
with the TNF antagonist etanercept (Irwin et al., 2009). Surpris-
ingly, in these human studies TNF blockade did not alter polysom-
nographic signs of NonREM sleep (Vgontzas et al., 2004; Irwin
et al., 2009), which contrasts with ﬁndings in rabbits, where i.c.v.
injection of a TNF receptor blocker mainly diminished NonREM
sleep (Takahashi et al., 1996b). Although primary effects of pro-
inﬂammatory cytokines on NonREM and SWS have been demon-
strated also in humans (e.g., Raison et al., 2010; Späth-Schwalbe
et al., 2000), to the best of our knowledge so far no attempts have
been made to speciﬁcally scrutinize the role of IL-1 for human
SWS.
Here, we investigated the effects of s.c. administration of a sin-
gle dose of the IL-1 receptor antagonist anakinra (IL-1ra) on sleep
in healthy humans. As the antagonist crosses the blood–brain bar-
rier (Cawthorne et al., 2011; Clark et al., 2008; Gutierrez et al.,
1994), we expected to replicate the suppressive effects on SWS
observed after i.c.v. administration of similar IL-1 antagonists in
animals (Opp and Krueger, 1991; Takahashi et al., 1997). Consider-
ing the well-known consolidating effect of SWS on hippocampus-
dependent declarative memory (Diekelmann and Born, 2010) as
well as ﬁndings that microglial-derived pro-inﬂammatory cyto-
kines contribute to hippocampal LTP, we also investigated effects
of IL-1ra on overnight consolidation of declarative memory
(word-pairs, texts). Finally, to gain hints on how central nervous
effects of IL-1ra are mediated, we monitored IL-1 production by
circulating monocytes, in parallel with sleep and overnight mem-
ory consolidation. In this context, we aimed to elucidate which
monocyte subpopulation (i.e., either CD14++CD16 or CD14dim-
CD16++ monocytes) can be used as a suitable model of brain
microglial IL-1 production, accessible to evaluation in human
blood (Anthony et al., 2005; Leone et al., 2006; Varvel et al., 2012).2. Material and methods
2.1. Subjects
Subjects were 16 healthy men aged on average
22.75 ± 0.93 years (range 18–31 years). Women were not included
in this study because of known interactions between sleep and the
menstrual cycle (e.g., Baker and Driver, 2007) and, thus, to reduce
inter-individual variance, although this limits generalizability of
results. Subject numbers were calculated by power analysis based
on results from other pharmacological studies using comparable
outcome measures (e.g., Feld et al., 2014; Groch et al., 2013). They
were non-smokers presenting a normal nocturnal sleep pattern
and did not take any medication at the time of the experiments.
Acute and chronic illness was excluded by medical history, physi-
cal examination, and clinical routine laboratory investigation. The
subjects had a regular sleep–wake rhythm for at least 6 weeks
before the experiments. Subjects were familiarized with the exper-
imental setting by spending an adaptation night in the laboratory
that included the attachment of electrodes for sleep recordingsand the insertion of an intravenous (i.v.) forearm catheter for blood
sampling. Written informed consent was obtained from each par-
ticipant, and the study was approved by the local ethics
committee.
2.2. Experimental design and procedure
The experiments were conducted in the sleep laboratories of
the University Hospital Schleswig–Holstein, Campus Luebeck, Ger-
many, according to a placebo-controlled within-subject crossover
design. Each man participated in two experimental conditions. In
one condition he was subcutaneously (s.c.) injected with the IL-
1ra anakinra (Kineret, Biovitrum, Sweden; 100 mg dissolved in
0.67 ml saline solution), half-life in plasma 4–7 h (Akash et al.,
2013; Chang et al., 2004); in the other condition placebo (saline
solution that was visually indistinguishable from anakinra) was
injected. Participants, examiners and people assessing the out-
comes of the measurements were all blinded to the condition.
The order of substance administration was balanced across sub-
jects, who were randomly allocated to one of the two possible
orders based on the automated calculation of a random number.
Both sessions for a subject were separated by an interval of at least
14 days. The lack of differences in baseline values of IL-1ra
between conditions proved that 2 weeks were sufﬁcient for the
drug being washed out, although this does not exclude that (unde-
tected) biological effects might have persisted for a much longer
time after the substance has been cleared from the body.
On experimental nights, participants arrived at the laboratory at
19:30 h. Following preparations for polysomnographic recordings,
they performed (between 21:00 and 22:30 h, always in the same
order) on a word pair associates learning task and a text learning
task, with a 10-min break between the tasks. After the learning
phase and 30 min before lights were turned off (at 23:00 h) to
enable sleep, the substance was administered. Blood samples were
taken at 20:30, 21:30, 22:30, 23:30 h, and then every hour until
6:30 h for analyses of hormone and IL-1ra concentrations and for
ﬂow cytometry. Blood was sampled via an i.v. forearm catheter
that was connected to a long thin tube and enabled blood collec-
tion from an adjacent room without disturbing the subject’s sleep.
The total volume of blood sampled during a session was 250 ml.
Subjects were awakened at 7:00 h and then left the lab. During
the following day participants engaged in their usual activities.
They were instructed to refrain from any stressful mental or phys-
ical activities, which were conﬁrmed by a record of their activities
during the day. In the evening they returned to the lab at 20:00 h
and retrieval of the memory tasks was tested – in reverse order of
learning and a last blood sample was taken. Possible side effects of
IL-1ra administration were excluded by a standardized interview
and questionnaire assessing drug awareness and symptoms like
dizziness, pain, headache, etc. on the morning after sleep and after
subjects returned to the lab in the evening. There were no signiﬁ-
cant side effects.
2.3. Polysomnography, sleep EEG analyses, and subjective sleep quality
Standard polysomnographic recordings were obtained includ-
ing electroencephalographic (EEG) recordings from electrodes
attached at C3 and C4 (according to the international 10–20 sys-
tem, referenced to electrodes attached to the mastoids) as well
as electrooculographic and electromyographic recordings. Signals
were ampliﬁed (Brain Amp, Brain Products, Germany) and digi-
tized, with the EEG sampled at a rate of 200 Hz and ﬁltered
between 0.16 and 70 Hz. Sleep stages were determined off-line
for subsequent 30-s recording epochs following standard criteria
(Rechtschaffen and Kales, 1968). Total sleep time (TST), and the
time spent in the different sleep stages (wake; stages 1, 2, 3, and
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TST. Sleep onset was deﬁned by the ﬁrst occurrence of stage 1 sleep
followed by stage 2 sleep. Sleep onset latency was determined with
reference to lights off. SWS was deﬁned as the sum of time spent in
stages 3 and 4 sleep. Latencies of SWS and REM sleep were
assessed with respect to sleep onset.
For a more ﬁne-grained analysis of NonREM sleep, EEG power
spectra were calculated applying Fast Fourier Transformation
(FFT; Vision Analyzer, Brain Products, Germany) on succeeding
10.24-s (2048 data points) epochs of NonREM sleep (S2, S3, S4)
or SWS (S3, S4). Only epochs free of movement or muscle artifacts
were used. Mean power density was determined for the 0.6–4 Hz
(slow wave activity) and the 12–15 Hz (spindle) frequency bands.
Mean power density was determined for the whole night, sepa-
rately for the ﬁrst and second night half.
Subjective sleep quality was evaluated using a modiﬁed version
of the sleep questionnaire SF-A/R (Görtelmeyer, 2011). Mood was
measured using the Positive and Negative Affect Schedule (PANAS).
Participants responded to items (e.g., ‘‘Do you momentarily feel
scared?’’) on a 5-point Likert scale ranging from 1 = ‘‘not at all’’
to 5 = ‘‘very much’’. Subjective sleepiness was assessed with the
Stanford Sleepiness Scale (SSS).
2.4. Memory tests
A declarative verbal paired associates task was applied that
required learning a list of 40 pairs of semantically related words
(e.g., clock–church). Different word lists were used on the subject’s
two experimental nights. During the learning phase, the word pairs
were presented sequentially on a computer screen, each for 3 s,
separated by inter-stimulus intervals of 500 ms. After presentation
of the entire list, performance was tested using a cued recall proce-
dure, i.e., the ﬁrst word (cue) of each pair was presented and the
subject had to name the associated second word (response). The
correct response word was then displayed for 1 s, regardless of
whether the response was correct or not, to allow re-encoding of
the correct word pair. The cued recall procedure was repeated until
the subject reached a criterion of 60% correct responses. The num-
ber of word pairs recalled at retrieval testing, relative to the num-
ber of word pairs recalled at the criterion trial during the learning
phase (with learning performance set to 100%), served as a mea-
sure of overnight retention.
In addition, a text learning task was applied. Two standardized
neutral German texts (‘‘Bronze’’ and ‘‘Fashion’’) which were vali-
dated in previous studies (Schürer-Necker, 1994) were used on
the subject’s two experimental nights. In the learning phase, the
subjects were instructed to carefully read the text, which was writ-
ten on a sheet of paper, within 4 min and tomemorize its content as
detailed as possible. After reading, subjects rated the text on
7-point Likert scales on the dimensions: comprehensible–
incomprehensible, interesting–uninteresting, difﬁcult–easy, neutral–
emotional, harmless–startling, important–unimportant, vivid–
abstract, amusing–serious, boring–arousing, familiar–unfamiliar,
positive–negative. Thereafter, in an immediate free recall test, the
participants were asked to write down the previously read text as
accurately as possible, without time restriction. This immediate test
served to determine how much information was initially encoded,
thereby providing an individual baseline value for recall perfor-
mance assessed at later retrieval testing after sleep on the next
morning. The number of correct content words recalled at retrieval
testing, relative to the number of correct content word recalled dur-
ing the learning phase (with learning performance set to 100%),
served as a measure of overnight retention. At retrieval testing, in
addition to free recall performance, memory for the temporal order
in the texts was assessed. In this test, 12 pairs of words were pre-
sented with one word of the pair representing a content word ofthe text and the other one a synonym. Subjects were required to
select the correct content words and order these words according
to the sequential order in which they occurred in the text. Recall
of sequential order was determined by a deviation score, that is,
the distance of the remembered sequence position for a content
word from its actual position in the story (Wilhelm et al., 2011).
2.5. Analyses of hormones and IL-1ra
Blood samples were kept frozen until assay. ACTH, cortisol,
growth hormone (GH), and prolactin were measured using the
Immulite assay (Siemens Healthcare Diagnostics, Erlangen, Ger-
many). Epinephrine and norepinephrine were measured by HPLC
(Chromsystems GmbH, Graefelﬁng, Germany). IL-1ra was detected
in plasma with an assay from Quantikine (R&D Systems, Wiesba-
den, Germany). Assay sensitivities were as follows: ACTH: 9 pg/
ml, cortisol: 0.2 lg/dl, epinephrine: 15 ng/l, GH: 0.1 ng/ml, IL-1ra:
18.3 pg/ml, norepinephrine: 15 ng/l, and prolactin: 0.5 ng/ml.
Intra-assay and inter-assay coefﬁcients of variations were all
<12.7%.
2.6. Flow cytometric analyses
Wemeasured cytokine production in two monocyte subpopula-
tions, i.e., classical monocytes (CD14++CD16) and non-classical
monocytes (CD14dimCD16++), without further stimulation as previ-
ously described (Selkirk et al., 2009). Blood was transferred into a
sodium heparin tube which was pre-spiked with Brefeldin A and
which was then immunostained with anti-CD14-PerCP and anti-
CD16-V500. FACS Permeabilizing Solution (BD Biosciences, Heidel-
berg, Germany) was added and nonspeciﬁc binding blocked using
Human TruStain (FcX Biozol Diagnostica, München, Germany).
After intracellular staining with anti-IL-1ra-PE, anti-IL-1b-FITC
(BD Biosciences, Heidelberg, Germany) and anti TNF-APC (BioLeg-
end, San Diego, California), blood was incubated for 30 min. 2 ml
special washing buffer (Cell Wash) were then added and washed
out with centrifugation at 500g for 10 min. Finally, the pellet was
re-suspended in 300 ll PBS, which included 2% of paraformalde-
hyde. At least 10,000 CD14+ cells were acquired and subsequently
analyzed for the production of intracellular IL-1, IL-1ra and TNF on
an LSR II ﬂow cytometer (BD Biosciences, Heidelberg, Germany).
Cytokine production was quantiﬁed as the percentage of cyto-
kine-positive cells as well as by analyzing the respective median
ﬂuorescence intensity (MFI).
2.7. Statistical analyses
Statistical analysis was based on analysis of variance (ANOVA),
including repeated-measures factors for the administered sub-
stance (IL-1ra versus placebo, ‘‘Substance’’) and for time points of
measurements (‘‘Time’’). EEG data, hormones, and immune param-
eters were analyzed for the total nights and, in addition, separately
for the ﬁrst and second half of the night. Analyses of hormones and
immune parameters included baseline measures (i.e., the average
of the ﬁrst three samples before drug administration) as covariate
when appropriate. There were no drop outs during the study, i.e.,
all 16 subjects completed both conditions. However, sample sizes
were reduced to n = 10–15 for the analyses of sleep stages, EEG
power, hormone concentrations and immune parameters, due to
the loss of EEG ﬁles (in 2 subjects), EEG artifacts (3 subjects), or
problems with blood sampling (3 subjects; please, refer to ﬁgure
legends for speciﬁc n). A CONSORT ﬂow chart summarizes the ﬂow
of the subjects at each phase (Supplementary Fig. 1). Degrees of
freedom were corrected using the Greenhouse–Geisser procedure.
Planned post hoc t-tests were applied to analyze differences at sin-
gle time points once ANOVA indicated signiﬁcant effects. Values
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means ± SEM.3. Results
3.1. Polysomnography, sleep EEG analyses, and subjective sleep quality
Compared with placebo, IL-1ra did not change TST and the
absolute or percent time spent in the different sleep stages. Also,
latency of SWS was comparable in both substance conditions (all
p > 0.28; Table 1). A more ﬁne-grained evaluation of EEG power
during periods of SWS and NonREM sleep indicated that IL-1ra
enhanced slow wave activity (0.6–4 Hz). For the analysis of SWS
the effect was highly signiﬁcant during the ﬁrst night half
(F(1,10) = 24.12, p = 0.001 for main effect of Substance, Fig. 1), for
the analyses of NonREM sleep (including periods of stage 2 sleep)
the effect was most pronounced in the second night-half
(F(1,11) = 6.02, p = 0.032 for main effect of Substance). Fast spindle
(12–15 Hz) activity did not differ between conditions (p > 0.22).
There were also no effects of IL-1ra on subjective sleep quality,
sleepiness or mood assessed in the next morning (Table 1).Fig. 1. Slow wave activity during Non-rapid eye movement (NonREM) sleep and
slow wave sleep (SWS) after administration of IL-1ra versus placebo. Slow wave
activity (power density in lV2/Hz) during NonREM sleep including sleep stages 2, 3
and 4 (upper panel) and during periods of SWS (lower panel) following adminis-
tration of IL-1ra (black bars) and placebo (white bars) for the ﬁrst and second half of
the night. Means ± SEM are indicated, n = 11–14, ⁄p < 0.05, ⁄⁄⁄p < 0.001 for pairwise
comparisons between IL-1ra and placebo conditions.3.2. Memory tests
Administration of IL-1ra did not affect the retention of declara-
tive memories for word pairs or texts. There were no differences
between conditions in the percentage of recalled word pairs (Pla-
cebo: 101.57 ± 2.53%; IL-1ra: 102.85 ± 2.59%, p = 0.70), the percent-
age of recalled content words of the text (Placebo: 89.75 ± 2.41%,
IL-1ra: 85.24 ± 3.72%, p = 0.35), or in the deviation score assessing
memory for the temporal order in the texts (Placebo:
27.94 ± 2.77, IL-1ra: 28.56 ± 2.33, p = 0.86) during the retrieval
phase. Additional analyses including IL-1ra concentration at retrie-
val testing as covariate likewise did not reveal any differences in
recall performance between the substance conditions (all
p > 0.415), thus excluding a confounding inﬂuence from residual
IL-1ra activity present during retrieval. Immediate recall of the
word pair associates (Placebo: 30.31 ± 1.08, IL-1ra: 29.13 ± 1.09;
number of trials to reach the criterion: Placebo: 2.13 ± 0.29, IL-le 1
ep and mood.
IL-1ra Placebo
Means SEM Means SEM
TST, min 424.47 4.64 414.13 12.40
W, % 3.79 1.42 1.63 0.41
S1, % 7.75 1.29 7.17 1.06
S2, % 60.79 2.49 62.04 1.59
S3, % 9.40 0.70 9.73 0.68
S4, % 1.47 0.68 1.43 0.73
REM, % 16.41 1.09 17.70 1.47
SWS, % 10.87 1.14 11.17 1.11
Sleep onset latency, min 25.10 2.82 26.40 6.07
SWS latency, min 27.60 10.04 19.77 0.90
REM latency, min 93.37 9.85 70.40 2.44
SQ 3.02 0.16 3.15 0.19
FRS 2.63 0.16 2.59 0.18
Positive affect 18.50 1.72 18.64 1.52
Negative affect 13.29 1.00 13.43 0.80
Subjective sleepiness 5.14 0.25 4.64 0.31
centage of total sleep time (TST) spent awake (W) and in sleep stages 1–4 (S1–
, slow wave sleep (SWS), and rapid eye movement (REM) sleep, latency of sleep
set (with reference to lights off), and of SWS and REM sleep (with reference to
ep onset), sleep quality (SQ), feeling of refreshment after sleep (FRS), positive and
gative affect (on the PANAS) and subjective sleepiness (SSS) measured in the
rning after sleep. Means (±SEM) are given for the IL-1ra and placebo conditions.
ere were no signiﬁcant differences between conditions.1ra: 1.88 ± 0.24) as well as of the texts (Placebo: 31.38 ± 2.39, IL-
1ra: 31.5 ± 4.17) at the end of the learning phase before retention
sleep were also comparable for both substance conditions
(pP 0.32, for all relevant comparisons).
3.3. Blood hormone and IL-1ra concentrations
IL-1ra administration, as expected, strongly increased IL-1ra
blood concentrations throughout the night, and also on the next
day (F(1,8) = 237.54, p < 0.001 for main effect of Substance, Fig. 2)
with this prolonged increase diverging from previous pharmacoki-
netic studies (Chang et al., 2004). Compared with placebo, IL-1ra
increased prolactin levels during the ﬁrst half of the night
(F(1,12) = 6.35, p = 0.027 for main effect of Substance) and decreased
cortisol levels (F(1,13) = 4.96, p = 0.044 for main effect of Substance).
IL-1ra also slightly decreased ACTH levels, although this effect was
not signiﬁcant. There were no systematic effects of the antagonist
on growth hormone and catecholamine concentrations (data not
shown).
3.4. Monocytes and expression of IL-1, TNF and IL-1receptor
antagonist (IL-1ra)
Under normal conditions, i.e., following placebo administration,
percentages of CD14++CD16 monocytes producing IL-1ra or TNF
remained stable across the night, whereas percentages of IL-1 pro-
ducing CD14++CD16 monocytes declined (from 6.85% at 20:30 h
to 4.88% at 6:30 h, F(10,120) = 4.82, p = 0.002 for main effect of Time).
Fig. 2. IL-1ra and hormone serum levels after administration of IL-1ra. Blood serum
concentrations of IL-1ra, prolactin, cortisol, ACTH, and growth hormone following
administration of IL-1ra (thick lines, black circles) and placebo (thin lines, open
circles). Means ± SEM are indicated, n = 10–15, ⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001 for
pairwise comparisons between IL-1ra and placebo conditions. Values are adjusted
to the ﬁrst three time points (baseline) based on covariance analysis. Gray area
indicates time in bed, top panel illustrates prototypical sleep proﬁle, arrows
indicate time of substance injection.
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TNF all rose across nighttime (F(10,120) > 3.15, p < 0.024 for maineffect of Time). The distinct time courses in cytokine production
conﬁrm that the two kinds of monocytes represent distinct sub-
types that are differentially regulated during the sleep–wake cycle
(Dimitrov et al., 2007).
Administration of IL-1ra increased the percentage of IL-1ra+
CD14++CD16 monocytes (F(1,12) = 15.39, p = 0.002 for main effect
of Substance) and the MFI (per cell) of IL-1ra (F(1,11) = 19.56,
p = 0.001 for main effect of Substance) in these cells, which might
simply reﬂect the binding of IL-1ra to IL-1 receptors on these cells.
Interestingly, IL-1ra concurrently decreased MFI for IL-1 in these
cells during the ﬁrst night-half (F(1,11) = 11.42, p = 0.006 for main
effect of Substance; Fig. 3). In CD14dimCD16++ monocytes, IL-1ra
did not affect production of IL-1ra, IL-1, or TNF (p > 0.125).4. Discussion
Studies in rodents and rabbits using blockers and activators of
IL-1 signaling have provided consistent evidence that IL-1 pro-
motes sleep, and speciﬁcally SWS (Krueger et al., 2007; Obál and
Krueger, 2003). Animal studies also revealed that this cytokine
supports memory formation and underlying synaptic plasticity
(del Rey et al., 2013; Goshen et al., 2007; Schneider et al., 1998;
Spulber et al., 2009). In the present study, we tested the effects
of inhibiting IL-1 signaling by the IL-1ra anakinra on sleep and
sleep-dependent memory consolidation for the ﬁrst time in
healthy humans. We expected that, like in animals, in the human
subjects of our study, IL-1ra would diminish SWS and disturb
sleep-dependent memory consolidation. Unexpectedly, the main
ﬁnding of this study was that IL-1ra did not diminish SWS, but
even enhanced EEG slow wave activity. Slow wave activity (0.6–
4 Hz) is the hallmark of SWS and is a measure of SWS intensity.
The effect was most pronounced in the early part of sleep, but
was observed for NonREM sleep including lighter sleep stage 2 also
in the second half of the night. We did not ﬁnd any change in reten-
tion of declarative memory after IL-1ra administration. However,
we found signiﬁcant changes in sleep-associated hormone secre-
tion: prolactin release was enhanced during the early night and
cortisol release was reduced during the late night after IL-1ra. In
classical monocytes, IL-1ra reduced IL-1 production, with this
effect emerging with some hours delay.
Overall the pattern of changes indicates that administration of
the IL-1ra was effective. Yet, why does the outcome of the present
experiments in humans diverge so strongly from the ﬁndings of
previous animal studies? It could be argued that the IL-1ra after
s.c. injection did not cross the blood–brain barrier and so did not
reach the brain. However, there is consistent evidence, although
from animal studies, that anakinra crosses the blood–brain barrier
after peripheral administration presumably through a saturable
transport process (Gutierrez et al., 1994; Skinner et al., 2009). Con-
ﬁrmatory evidence that anakinra reaches the brain in humans has
been so far obtained only in patients with subarachnoid hemor-
rhage (Clark et al., 2008; Galea et al., 2011). In line with previous
ﬁndings blood levels of IL-1ra at baseline were 200 pg/ml and
then showed a 10,000 fold increase after anakinra administration
(Chang et al., 2004; Frey et al., 2007). Although with peripheral
administration levels of IL-1ra achieved per gram brain tissue are
only 0.01–0.6% of the injected dose, such levels are within the
range of drugs known to produce strong neuromodulatory actions
(e.g., Cawthorne et al., 2011; Clark et al., 2008; Gutierrez et al.,
1994). Accordingly, peripheral administration of IL-1ra proved to
exert potent anti-inﬂammatory actions in the brain in animals
and humans (Clark et al., 2008; Garcia et al., 1995; Relton et al.,
1996). Altogether, this excludes that the systemic route of admin-
istration per se can explain the divergence in the ﬁndings here and
in previous animal studies. On the contrary, it seems justiﬁed to
Fig. 3. IL-1 and TNF production in classical and non-classical monocytes. Median ﬂuorescence intensity (MFI) for (A) IL-1 and (B) TNF on classical (CD14++CD16) and non-
classical (CD14dimCD16++) monocytes following administration of IL-1ra (thick lines, solid circles) and placebo (thin lines, open circles). Means ± SEM are indicated, n = 13,
⁄p < 0.05 for pairwise comparisons between IL-1ra and placebo conditions. Values are adjusted to the ﬁrst three time points (baseline) based on covariance analysis. Gray area
indicates time in bed, arrows indicate time of substance injection.
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clinical standard criteria for the treatment of rheumatoid arthritis
(Chang et al., 2004) and led to very high plasma levels within 2 h
after administration, effectively blocked the action of endogenous
IL-1 in the brain. Still this assumption needs to be scrutinized by
direct measures of central nervous IL-1ra levels, e.g., in cerebrospi-
nal ﬂuid, which were not performed here.
The dose of IL-1ra administered resulted in clearly supra-phys-
iological concentrations of the antagonist in the blood, and IL-1ra
increased the release of prolactin and reduced cortisol levels. Thus,
rather than directly acting on the central nervous system, IL-1ra
might have increased slow wave activity via inducing speciﬁc sys-
temic hormonal changes. Indeed, the increase in prolactin after IL-
1ra is consistent with previous studies showing that IL-1 inhibits
prolactin secretion (Bernton et al., 1987) and that IL-1ra can
increase prolactin secretion (Tanaka et al., 2000). The latter study
used in vitro stimulation of pituitary cells, indicating that prolactin
release can basically result from blood-borne IL-1ra. Prolactin
secretion is known to run in parallel with slow wave activity dur-
ing SWS in healthy men (Spiegel et al., 1995) and high serum levels
of prolactin in breast feeding mothers were associated with
increases in slow wave activity (Nishihara et al., 2004). However,
these ﬁndings are correlative in nature. Importantly, animal stud-
ies administering prolactin and studies in prolactin knockout mice
revealed that the hormone enhances REM sleep, but does not
induce any consistent change in SWS (Obál et al., 2005; Zhang
et al., 1999). Against this backdrop it is unlikely that enhanced pro-
lactin mediated the effects of IL-1ra in the present study. Rather,
the joint increase in EEG slow wave activity and prolactin concen-
trations after IL-1ra speaks for the view that the antagonist acts on
a central nervous mechanism naturally coupling both phenomena.
Decreased cortisol release after IL-1ra can be likewise excluded
as factor mediating the enhancing effects of IL-1ra on slow wave
activity. This decrease is well in line with ﬁndings in animals of a
stimulatory effect of IL-1 on hypothalamus–pituitary–adrenal
secretory activity (Besedovsky et al., 1986; Gadek-Michalska and
Bugajski, 2010; Uehara et al., 1987). However, here the decrease
in cortisol concentration was rather small, without concomitant
robust decreases in ACTH concentrations, and limited to the second
night-half, whereas increases in slow wave activity were most pro-
nounced during the ﬁrst night-half. Also, increases in early night
SWS were found to be a consequence of increases rather than
decreases in blood cortisol levels (Born et al., 1989). BecauseSWS blocks pituitary-adrenal secretory activity (Bierwolf et al.,
1997) the decrease in cortisol following IL-1ra might rather be
viewed as a consequence of the central nervous enhancement in
slow wave activity after IL-1ra administration.
To the best of our knowledge, so far the speciﬁc effects of IL-1ra
on spontaneous sleep has been examined by only one study in rab-
bits which revealed a transient reduction in the duration of Non-
REM sleep in the ﬁrst hour after i.c.v. injection of an
intermediate dose (0.025 mg/kg), but not after a high dose
(0.25 mg/kg) of the antagonist (Opp and Krueger, 1991). Animal
studies using other methods of blocking IL-1 signaling (like anti-
bodies against IL-1) showed even more robust reductions of Non-
REM sleep both after central and peripheral administration of the
employed substance (Opp and Krueger, 1994a,b; Takahashi et al.,
1996a, 1997). Moreover, some animal studies indicated increases
in slow wave activity following enhancing IL-1 signaling and
decreased slow wave activity following disruption of IL-1 signaling
(Opp and Krueger, 1994a; Takahashi et al., 1996a), although occa-
sionally discrepant results were obtained especially following
intraperitoneal administration of IL-1 in rodents (Fang et al.,
1998; Hansen and Krueger, 1997). Overall, these results in rats,
mice and rabbits appear to be in stark contrast to our ﬁnding of
increased slow wave activity after IL-1ra administration with no
signiﬁcant effects on SWS duration. This might reﬂect species spec-
iﬁcity of the effect of IL-1ra, although species speciﬁcities in the
organization of SWS might also be of relevance. For example, in
humans SWS is embedded in lighter NonREM sleep stages which
are not differentiated in rodents. Species speciﬁcities between
humans and animals, and also between mice, rats and rabbits have
been observed for numerous other immune factors (Mestas and
Hughes, 2004). Indeed, several previous studies also found distinct
species differences in the impact of cytokine administration and
infections on sleep architecture (Irwin et al., 2009; Pollmächer
et al., 2000; Raison et al., 2010; Zamarrón et al., 2004).
Brain microglia has been identiﬁed as a crucial source of IL-1
and TNF promoting SWS (Krueger et al., 2008; Rothwell, 1999).
Because it is not possible to study human microglia in vivo, we
measured cytokine expression in monocyte subsets, based on evi-
dence suggesting that monocytes, which share the same precursor
cells as microglia, might be a potential model for microglial IL-1
production (Anthony et al., 2005; Leone et al., 2006; Varvel et al.,
2012). Indeed, in the placebo condition IL-1 producing classical
monocytes showed the expected time course with peak percent-
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icking the reported temporal dynamics of IL-1 in brain parenchyma
and cerebrospinal ﬂuid (Cearley et al., 2003; Lue et al., 1988; Taishi
et al., 1997). IL-1ra selectively decreased production of IL-1 in
these classical CD14++CD16 monocytes, but not in non-classical
CD14dimCD16++ monocytes. The pattern is in line with the well-
known stimulatory effect of IL-1 on its own production
(Dinarello et al., 1987), suggesting the presence of such positive
feedback loop for the production of IL-1 also in classical mono-
cytes. It ﬁts also with observations by Conti et al. (1992) of an inhi-
bition of IL-1 in human monocytes after in vitro administration of
IL-1ra as well as with observations by Burger et al. (2009) of
reduced IL-1 production in multiple sclerosis patients exhibiting
simultaneously increased IL-1ra levels. Collectively, these ﬁndings
imply a twofold synergistic action of IL-1ra in the brain, namely by
directly blocking neuronal IL-1 receptors and by additionally
decreasing brain IL-1 production in microglia.
Overall, our ﬁndings indicate that IL-1ra strengthens SWS by
enhancing EEG slow wave activity, with a concomitant increase
in prolactin release. The effects very likely reﬂect central nervous
actions of IL-1ra involving both direct actions on neuronal IL-1
receptors as well as a decrease in brain borne IL-1. In diverging
from animal studies these ﬁndings suggest species speciﬁcities to
play a role in the effects of IL-1 on sleep. However, this conclusion
requires further experimentation, particularly in light of the fact
that our study is based on testing of just one speciﬁc drug admin-
istered through one speciﬁc route at only one dose, inducing supra-
physiological IL-1ra concentrations in blood that might have indi-
rectly impacted brain function. For a clearer differentiation
between the effects of IL-1 on sleep in the different species, differ-
ent doses and routes of administration need to be tested also in
humans. For example the intranasal route of administration might
allow for testing direct central nervous effects of the IL-1ra in
healthy volunteers (Born et al., 2002). Beyond this issue, the pres-
ence of species speciﬁcities in the effects of IL-1 eventually under-
lines the urgent need of directly probing cytokine functions in the
human being.
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